SciSparc to Commence Its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
Portfolio Pulse from Benzinga Newsdesk
SciSparc Ltd. (NASDAQ:SPRC) has received approval from the Israeli Medical Cannabis Agency to conduct a clinical trial for SCI-210, a proprietary combination of cannabidiol and CannAmide™, in children with autism spectrum disorder. The company has secured all necessary approvals to commence the trial in Israel and aims to sell SCI-210 first in Israel and then globally, subject to regulatory approvals.
July 14, 2023 | 11:56 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
SciSparc's approval to conduct a clinical trial for SCI-210 in children with autism could potentially open a new market for the company. Success in the trial and subsequent regulatory approvals could boost the company's revenues.
The approval to conduct a clinical trial for SCI-210 in children with autism is a significant step for SciSparc. If the trial is successful and the product receives further regulatory approvals, it could potentially open a new market for the company, leading to increased revenues. This could have a positive impact on the company's stock price in the short term.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100